Promising cancer drug trial halted early – only 5 patients enrolled

NCT ID NCT06198426

Terminated Disease control Sponsor: Innovent Biologics (Suzhou) Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested an experimental drug called IBI3004 in people with advanced solid tumors that could not be removed by surgery. The study aimed to find a safe dose and check for side effects, but it was terminated after enrolling only 5 participants. Because it stopped so early, we have very little information about how well the drug works or what risks it may carry.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IBI3004 (an experimental drug)
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumors.
What could go wrong: This trial was terminated early with only 5 participants, so results are very limited. The drug is still in early testing and may not prove safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR

Contacts and locations

Locations

Jiang Su Province Hospital

Nanjing, Jiangsu, 210024, China
Liverpool Hospital

Sydney, New South Wales, 2170, Australia
Scientia Clinical Research Ltd

Randwick, New South Wales, 2770, Australia
The Second Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310009, China
Westmead Hospital

Sydney, New South Wales, 2170, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.